# Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye

> **NCT02101281** · PHASE2 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 40 (actual)

## Conditions studied

- Dry Eye Syndrome

## Interventions

- **DRUG:** rhNGF 20 µg/mL
- **DRUG:** rhNGF 4 µg/mL

## Key facts

- **NCT ID:** NCT02101281
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-20
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02101281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02101281, "Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02101281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*